The Pennant Group, Inc.
NASDAQPNTG heads into its Q2 print today with a clear tension between bullish analyst conviction and persistent selling by the company's own chief executive. The most striking signal ahead of earnings is the insider activity. CEO Brent Guerisoli sold shares twice in early July — roughly 3,159 shares on July 10 at $41.57 and 3,165 shares on July 7 at $40.51 — adding to a pattern of sales…
PNTG short interest jumped 37% over one week to 2.18% of float, driven by rising short positions as occupancy gains face Medicare Advantage headwinds.
Snapshot as of 6 Aug 2026
PNTG heads into its Q2 print today with a clear tension between bullish analyst conviction and persistent selling by the company's own chief executive. The most striking signal ahead of earnings is the insider…
The Pennant Group has had an eventful week — a blowout Q1 print drove the stock up 13%, analysts lifted targets across the board, and short sellers retreated sharply. Then, on Wednesday, the Centers for Medicare &…
PNTG heads into its Q1 2026 print with a market that has been decisively re-rating the stock higher — and analysts chasing it. The setup is one of quiet confidence rather than defensive hedging. Short interest is…
The Pennant Group enters the post-earnings session with a clean beat on both the top and bottom line — and a short base that has been quietly shrinking for weeks. Q1 2026 results, released on May 6, showed adjusted EPS…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PNTG — free to start on ORTEX.
Sign up for free →Open PNTG on ORTEX